Your browser doesn't support javascript.
loading
Engineering the IL-4/IL-13 axis for targeted immune modulation.
Bernstein, Zachary J; Shenoy, Anjali; Chen, Amy; Heller, Nicola M; Spangler, Jamie B.
Afiliación
  • Bernstein ZJ; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Shenoy A; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Chen A; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Heller NM; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Spangler JB; Department of Molecular and Cellular Biology, Johns Hopkins University, Baltimore, Maryland, USA.
Immunol Rev ; 320(1): 29-57, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37283511
ABSTRACT
The structurally and functionally related interleukin-4 (IL-4) and IL-13 cytokines play pivotal roles in shaping immune activity. The IL-4/IL-13 axis is best known for its critical role in T helper 2 (Th2) cell-mediated Type 2 inflammation, which protects the host from large multicellular pathogens, such as parasitic helminth worms, and regulates immune responses to allergens. In addition, IL-4 and IL-13 stimulate a wide range of innate and adaptive immune cells, as well as non-hematopoietic cells, to coordinate various functions, including immune regulation, antibody production, and fibrosis. Due to its importance for a broad spectrum of physiological activities, the IL-4/IL-13 network has been targeted through a variety of molecular engineering and synthetic biology approaches to modulate immune behavior and develop novel therapeutics. Here, we review ongoing efforts to manipulate the IL-4/IL-13 axis, including cytokine engineering strategies, formulation of fusion proteins, antagonist development, cell engineering approaches, and biosensor design. We discuss how these strategies have been employed to dissect IL-4 and IL-13 pathways, as well as to discover new immunotherapies targeting allergy, autoimmune diseases, and cancer. Looking ahead, emerging bioengineering tools promise to continue advancing fundamental understanding of IL-4/IL-13 biology and enabling researchers to exploit these insights to develop effective interventions.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interleucina-4 / Interleucina-13 Límite: Humans Idioma: En Revista: Immunol Rev Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interleucina-4 / Interleucina-13 Límite: Humans Idioma: En Revista: Immunol Rev Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos